Shared more. Cited more. Safe forever.
    • advanced search
    • submit works
    • about
    • help
    • contact us
    • login
    View Item 
    •   MOspace Home
    • University of Missouri-Columbia
    • School of Medicine (MU)
    • Department of Family and Community Medicine (MU)
    • Family Physicians Inquiries Network (MU)
    • Clinical Inquiries (MU)
    • Clinical Inquiries, 2004
    • View Item
    •   MOspace Home
    • University of Missouri-Columbia
    • School of Medicine (MU)
    • Department of Family and Community Medicine (MU)
    • Family Physicians Inquiries Network (MU)
    • Clinical Inquiries (MU)
    • Clinical Inquiries, 2004
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    advanced searchsubmit worksabouthelpcontact us

    Browse

    All of MOspaceCommunities & CollectionsDate IssuedAuthor/ContributorTitleSubjectIdentifierThesis DepartmentThesis AdvisorThesis SemesterThis CollectionDate IssuedAuthor/ContributorTitleSubjectIdentifierThesis DepartmentThesis AdvisorThesis Semester

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular AuthorsStatistics by Referrer

    Is combining ACE inhibitors and ARBs helpful or harmful?

    Chavey, William E.
    Nashelsky, Joan
    View/Open
    [PDF] IsCombiningACEInhibitors.pdf (55.39Kb)
    Date
    2004
    Format
    Article
    Metadata
    [+] Show full item record
    Abstract
    The combination of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) has been studied for treatment of heart failure, hypertension, and proteinuric renal disease. Combination therapy with an ACE inhibitor and an ARB decreases symptoms in heart failure patients, but does not appear to have an impact on overall mortality (strength of recommendation [SOR]: A). Preliminary data from small trials indicate that combination therapy may be more effective than monotherapy with an ACE inhibitor or an ARB for lowering blood pressure (SOR: B), although morbidity and mortality data for the combination are not currently available. Additionally, in trials involving diabetic and nondiabetic proteinuric renal disease, the combination of ACE inhibitors and ARBs delays progression of renal disease to a greater extent than monotherapy; however, mortality data are also unavailable (SOR: A).
    URI
    http://hdl.handle.net/10355/3181
    Part of
    Journal of family practice, 53, no. 02 (February 2004)
    Rights
    OpenAccess.
    This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.
    Collections
    • Clinical Inquiries, 2004

    Send Feedback
    hosted by University of Missouri Library Systems
     

     


    Send Feedback
    hosted by University of Missouri Library Systems